Kesimpta
My Prescription
Payment
Select pharmacy
$9,781.44
$30.00 due at pharmacy
$9,781.44 - $30.00 = $9,751.44
$9,751.44 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
AlbertsonsPowered by$9,781.44
Print or send this coupon to your phone
AlbertsonsPowered byAbout Kesimpta
Drug Details
Kesimpta (ofatumumab) is a medication used to manage relapsing forms of multiple sclerosis (MS). It is a type of monoclonal antibody that works by targeting certain immune system cells. These cells, if left unchecked, may mistakenly attack the nerve coverings in the brain and spinal cord, leading to MS symptoms. While Kesimpta is not a cure for MS, it helps to reduce the frequency of relapses and may delay the progression of disability associated with the disease. Kesimpta is administered as an injection under the skin. Initially, it is given weekly for the first month, and then once a month thereafter. The medication is available in a Sensoready Pen, which some patients may find easier to use compared to pre-filled syringes. Common side effects include an increased risk of infections and localized pain or swelling at the injection site. As with any medication, it's important to discuss with your healthcare provider whether Kesimpta is suitable for you, considering your specific health needs and conditions.
Price history for Kesimpta
1 Pen, 0.4ML of 20MG/0.4ML
Average retail price for Kesimpta
Average SaveHealth price for Kesimpta
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Kesimpta dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.4ML of 20MG/0.4ML | 1 Pen | $9,781.44 | $9,781.44 |
| 0.4ML of 20MG/0.4ML | 2 Pens | $19,545.88 | $9,772.94 |
| 0.4ML of 20MG/0.4ML | 3 Pens | $29,310.31 | $9,770.10 |
Kesimpta FAQs
Kesimpta is used for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The duration a patient can stay on Kesimpta (ofatumumab) is determined by their healthcare provider based on the individual's response to the treatment and any side effects experienced. There is no specific maximum duration established, and treatment can continue as long as it remains effective and the patient tolerates it well. Regular monitoring and consultations with a healthcare provider are essential to assess the ongoing suitability of the medication.
The cost of Kesimpta can vary based on factors such as insurance coverage, location, and pharmacy. Without insurance, the list price for Kesimpta is approximately $6,900 per month, which totals around $82,800 annually. However, patients are encouraged to check with their insurance provider and explore patient assistance programs that may significantly reduce out-of-pocket expenses.
The choice between Kesimpta and Ocrevus depends on various factors, including the specific medical condition being treated, the patient's health profile, and their response to previous treatments. Both medications are used to treat multiple sclerosis, but they have different administration methods and dosing schedules. Kesimpta is administered as a subcutaneous injection, while Ocrevus is given as an intravenous infusion. The decision on which medication is better should be made by a healthcare provider, who can consider the patient's individual needs and preferences.
The duration a patient can stay on Kesimpta (ofatumumab) is determined by their healthcare provider based on the individual's response to the treatment and any side effects experienced. There is no specific maximum duration for using Kesimpta, and it can be continued as long as it remains effective and well-tolerated. Regular monitoring and consultations with a healthcare provider are essential to assess the ongoing suitability of the treatment.